AZN.L - AstraZeneca PLC
| Previous close | 5,551.00 |
| Open | 5,589.00 |
| Bid | 5,100.00 x 6100 |
| Ask | 5,750.00 x 13000 |
| Day's range | 5,579.00 - 5,658.37 |
| 52-week range | 4,260.00 - 5,658.37 |
| Volume | 2,016,024 |
| Avg. volume | 2,228,627 |
| Market cap | 71.009B |
| Beta | 0.96 |
| PE ratio (TTM) | 25.32 |
| EPS (TTM) | 221.40 |
| Earnings date | 26 Jul 2018 |
| Forward dividend & yield | 2.02 (3.91%) |
| Ex-dividend date | 2018-02-15 |
| 1y target est | 73.38 |
- Reuters•10 hours ago
AstraZeneca to stockpile drugs as Brexit 'safety net'
AstraZeneca (AZN.L) is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the other way. A company spokesman said on Wednesday that AstraZeneca currently held several months of supplies of such medicines and this was being increased for products on both sides of the Channel.
- Reuters - UK Focus•10 hours ago
AstraZeneca to stockpile drugs as Brexit 'safety net'
AstraZeneca (NYSE: AZN - news) is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the other way.
- Fool.co.uk•yesterday
Forget the State Pension: AstraZeneca could help you to enjoy a prosperous retirement
AstraZeneca plc (LON: AZN) appears to offer strong dividend growth potential.
- Fool.co.uk•2 days ago
These 2 FTSE 100 stocks could give you a comfortable retirement
Your retirement portfolio could benefit significantly from these FTSE 100 (INDEXFTSE: UKX) stocks.
Market Realist•5 days agoAstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer
On June 27, AstraZeneca (AZN) and Merck (MRK) reported positive data for their Phase 3 Lynparza trial, SOLO-1, a randomized, double-blind, placebo-controlled trial for ovarian cancer. The drug met the primary endpoint of progression-free survival in women with BRCA1-mutated advanced ovarian cancer. Lynparza is the only PARP2 inhibitor to show significant activity in a first-line maintenance setting. Based on this data, the two companies plan to initiate discussions with authorities for regulatory submissions.
- MarketWatch•5 days ago
Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial
Shares of the biotech company Advaxis Inc. (ADXS) surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The trial is testing a combination of Advaxis' axalimogene filolisbac, a listeria-based immunotherapy, and Astrazeneca's durvalumab (AZN) for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.
Reuters•6 days agoFTSE 100 recovers, driven by defensives, as trade nerves ebb
By Helen Reid LONDON (Reuters) - British shares bounced back on Thursday, driven by financial and consumer stocks, as investor worries eased and another bid for pay-TV firm Sky boosted its stock. The FTSE ...
- Reuters - UK Focus•6 days ago
FTSE 100 recovers, driven by defensives, as trade nerves ebb
British shares bounced back on Thursday, driven by financial and consumer stocks, as investor worries eased and another bid for pay-TV firm Sky boosted its stock. The FTSE 100 ended the session up 0.8 ...
- The Wall Street Journal•12 days ago
[$$] Difficult Conversation: When the Harasser Is a Client
At many companies, client relationships are the most difficult to police – and the most important to protect. A former vice president at market-data firm Research Now SSI alleged in a lawsuit filed in April that a senior executive from the airline Virgin America, Stuart Dinnis, began kissing and groping her without warning in a hotel elevator late at night during a 2016 travel-industry conference. Earlier that day, she and her boss had discussed Mr. Dinnis, then Virgin America’s director of loyalty, as an important client to cultivate during the conference.
- Zacks•12 days ago
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
Reuters•12 days agoHitting cancer early: AstraZeneca's bid to outmaneuver rivals
AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumors before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumors.
- Reuters•12 days ago
Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals
AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumours before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumours.
- Market Realist•15 days ago
AstraZeneca’s Imfinzi and Lynparza Receive Approval in Japan
AstraZeneca (AZN) received two key regulatory approvals this week in Japan. On July 2, its immunotherapy drug Imfinzi was approved by Japan’s Ministry of Health, Labour and Welfare for lung cancer patients whose disease was inoperable and has advanced locally but has not widely spread throughout the body. It has been approved as a maintenance therapy after definitive chemoradiation therapy (or CRT).
- Zacks•15 days ago
AstraZeneca's Two New Cancer Drugs Get Approval in Japan
AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.
Reuters•16 days agoAstraZeneca wins speedy approvals for cancer drugs in Japan
LONDON (Reuters) - AstraZeneca (AZN.L) has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. ...
- Reuters - UK Focus•16 days ago
AstraZeneca wins speedy approvals for cancer drugs in Japan
AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. The decisions by the ...
Reuters•21 days agoAstraZeneca, Merck eye $1 billion boost from cancer drug success
AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment. The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck & Co under a deal struck last year. Lynparza is already approved for later use in patients with so-called BRCA genetic mutations.
- Reuters - UK Focus•21 days ago
AstraZeneca, Merck eye $1 bln boost from cancer drug success
AstraZeneca (NYSE: AZN - news) 's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment. Lynparza is already approved for later use in patients with so-called BRCA genetic mutations. Its latest success could expand the number of women with newly diagnosed ovarian cancer who are suitable for the drug by 30-50 percent, AstraZeneca (Swiss: AZN.SW - news) believes.
- Reuters - UK Focus•21 days ago
AstraZeneca, Merck eye wider cancer drug use after study success
AstraZeneca (NYSE: AZN - news) 's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment. The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck & Co (Swiss: MRK-USD.SW - news) under a deal struck last year. Lynparza is already approved for later use in patients with so-called BRCA genetic mutations.
- Motley Fool•24 days ago
Long-Term Investors Take Note -- These 5 Big Pharma Companies Have the Best Pipelines
These drugmakers arguably have the strongest pipelines. But are they all great stocks to buy?
- Market Realist•28 days ago
Lynparza Could Be Merck’s Long-Term Growth Driver
Merck & Company (MRK) and AstraZeneca (AZN) jointly develop and commercialize Lynparza. In June, Merck and AstraZeneca presented data from the Study 08 trial, in which a combination of Lynparza and abiraterone demonstrated an improvement in median radiologic progression-free survival (or rPFS) compared to abiraterone monotherapy.
- Zacks•last month
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
- The Wall Street Journal•last month
[$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials
AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.
- Investor's Business Daily•last month
AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap
AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.
- Zacks•last month
Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
